U.S. drugmakers could be impacted by the Trump administration’s proposed tariff on thousands of Chinese goods, which includes pharmaceutical products and ingredients used in drug manufacturing — including epinephrine, psychotherapeutic agents, antidepressants and lidocaine, among others.
Source: Drug Industry Daily